Drugs / Licensed IIV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05501561 Comparator | Aug 2022 → Mar 2023 | influenza | Seqirus | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Licensed IIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05501561 ↗ |
| Modality | Vaccine | “Biological/Vaccine: Licensed IIV Licensed Non-adjuvanted Quadrivalent Influenza vaccine” NCT05501561 ↗ |